Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
05:14pm, Monday, 01'st Jun 2026
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
08:00am, Monday, 01'st Jun 2026
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
07:30am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the [url="]ENZAMET trial[/url] presented at the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoi
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
05:17am, Thursday, 28'th May 2026
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth,
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
12:11pm, Wednesday, 27'th May 2026
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Veracyte genomic test identifies breast cancer patients who can skip chemo
07:22am, Wednesday, 27'th May 2026
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
12:20pm, Monday, 25'th May 2026
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
10:51am, Monday, 25'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
08:00am, Friday, 22'nd May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 20
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
06:00pm, Thursday, 21'st May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Veracyte to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 19'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Grow
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
10:45am, Monday, 18'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
